Post allogeneic hematopoietic transplant ebstein barr virus related lymphproliferative disorder following conditioning with antithymocyte globulin or alemtuzumab.
Study #: IN14-01
Study Status: Published
Presentation(s)
2018, Tandem (Poster)
Survival outcomes of allogeneic hematopoietic cell transplants with EBV‐positive or EBV‐negative post‐transplant lymphoproliferative disorder, a CIBMTR study.
Citation
Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.
Transplant Infectious Disease. 2019, Oct 01: 21(5): 21(5):e13145. doi: 10.1111/tid.13145. Epub 2019, Jul 12. PMCID:PMC7239317.
PubMed
PMID: 31301099
Abstract